SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Both organisations enter into a long- term collaboration to expand patient access in India
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
